Status:
TERMINATED
The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Advanced Malignancies
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
To evaluate the effects of patupilone on the pharmacokinetics of warfarin in patients with advanced malignancies.
Eligibility Criteria
Inclusion
- Inclusion criteria Participation in study EPO906A2120E1
- Age ≥ 18 years of age
- Life expectancy ≥ 3 months
- Histologically documented advanced solid tumors which have progressed after standard systemic therapy or for which standard systemic therapy does not exist
- Completed all PK sampling in the core study
- Exclusion criteria
- Known diagnosis of human immunodeficiency virus (HIV) infection, hepatitis
- Female patients who are pregnant or breast feeding
- Patients with a severe and/or uncontrolled medical disease
- Other protocol-defined inclusion/exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00468260
Start Date
May 1 2007
Last Update
November 19 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
San Antonio, Texas, United States